Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 18, 2023 14:28 ET | Source: Millicom International Cellular S.A.

Millicom (Tigo) notice of first quarter 2023 results and video conference

Millicom (Tigo) notice of first quarter 2023 results and video conference Luxembourg, April 18, 2023 – Millicom expects to announce its first quarter 2023 results on April 27, 2023 via a press...
October 10, 2019 09:30 ET | Source: Summit Therapeutics plc

Notice of Results

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2019 on 11 October 2019 Oxford, UK, and...
September 20, 2019 13:00 ET | Source: Millicom International Cellular S.A.

Notice of third quarter 2019 results and conference call

Notice of third-quarter 2019 results and conference call Luxembourg, 20 September 2019 – Millicom will announce its third-quarter results for the period ending 30 September 2019, on 23 October...
June 05, 2019 09:00 ET | Source: Summit Therapeutics plc

Notice of First Quarter Results

Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2019 Oxford, UK, and Cambridge, MA, US, 5 June 2019...
December 04, 2017 07:00 ET | Source: Summit Therapeutics plc

Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 2017

OXFORD, United Kingdom, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
March 27, 2017 07:00 ET | Source: Summit Therapeutics PLC

Summit Therapeutics Provides Notice of Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017

OXFORD, United Kingdom, March 27, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...